Archived Press Releases
The news releases presented here were believed to be accurate at the time they were issued and are provided for historical reference purposes only. They contain information that may no longer be accurate. Readers should not rely on the continued accuracy of any such material. All readers should carefully check the dates of issuance of the releases. NeurogesX assumes no obligation and does not intend to update, correct or otherwise modify any of these press releases regarding events that occur after their original release.
- May 14, 2004
NeurogesX Study Showing Single 1-Hour Dermal Application Results in 12 Weeks of Sustained Neuropathic Pain Reduction - April 29, 2004
NeurogesX Studies Show Single 1-Hour Dermal Application Results in 12 Weeks of Sustained Neuropathic Pain Reduction - March 9, 2004
Genencor Chairman Joins NeurogesX Board - February 24, 2004
NeurogesX Receives Million in Series C Round - February 9, 2004
Significant Pain Reduction for Painful HIV-Associated Neuropathy Demonstrated in NeurogesX Pilot Study - January 21, 2004
NeurogesX Appoints Michael Markels to Lead Sales & Marketing
